Exciting Developments in Fabry Disease Treatment
Totality of data supports the potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care.
Positive Results from the STAAR Study
The STAAR study revealed a significant positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks among all patients who received the treatment. This statistic is pivotal, as it has been agreed upon by the U.S. Food and Drug Administration (FDA) to serve as the primary basis for approval.
Safety and Tolerability Profile
Isaralgagene civaparvovec demonstrated an encouraging safety and tolerability profile during the study, reinforcing its potential as a transformative option for patients.
Presentation Highlights from the International Congress
Recently, Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leading genomic medicine company, shared breaking news regarding the registrational Phase 1/2 STAAR study focused on isaralgagene civaparvovec, also known as ST-920. This thorough presentation took place at the esteemed International Congress of Inborn Errors of Metabolism 2025 (ICIEM2025) held in Kyoto, Japan.
During the presentation, it became evident that these data illustrate the potential of ST-920 to deliver significant clinical benefits for individuals suffering from Fabry disease. Dr. John Bernat, an investigator in the study, emphasized the favorable results showing improvements in eGFR, comparable to those from current approved Fabry disease treatments, which is encouraging for patients facing declining renal and cardiac function.
Nathalie Dubois-Stringfellow, the Chief Development Officer at Sangamo, echoed this enthusiasm. She highlighted the critical need for effective treatments for Fabry disease due to its debilitating nature and expressed excitement over ST-920's potential to provide long-lasting improvements in renal and cardiac function, thereby enhancing patients' quality of life.
Key Findings from the Updated STAAR Study
The STAAR study, which enrolled 32 participants who received the treatment for at least 12 months, has produced remarkable efficacy results. Key outcomes include:
- A positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks, demonstrating notable efficacy.
- For those patients followed for 104 weeks, the mean eGFR slope remained positive at 1.747 mL/min/1.73m2/year.
- Stability in cardiac function indicators, such as left ventricular mass and myocardial strain, was reported, further validating the treatment's effectiveness.
- Additionally, all patients who started on Enzyme Replacement Therapy (ERT) successfully transitioned off ERT, retaining stability in their condition post-treatment.
Furthermore, significant quality of life improvements were reflected in the short-form health surveys, highlighting the positive impact of the treatment on physical and mental well-being.
Future Directions for Sangamo
Sangamo plans to submit a Biologics License Application (BLA) in the near future, aiming for early 2026 under the Accelerated Approval pathway. This proactive step indicates their commitment to bringing this potentially groundbreaking treatment to market to benefit patients with Fabry disease.
The study incorporated male and female patients, some currently on ERT, others off it for six months, or treatment-naïve, showcasing a diverse participant pool. The median age of those enrolled was 42, with follow-up durations varying from 24 months to 4.5 years for the longest-treated individual.
Isaralgagene civaparvovec holds special designations from the FDA and other regulatory bodies, including Orphan Drug, Fast Track, and RMAT, further underpinning its significance in tackling unmet medical needs.
As BLA preparation activities progress, Sangamo continues pursuing business development and potential collaborations for future commercialization of this promising therapy.
About Fabry Disease and Sangamo Therapeutics
Fabry disease is a severe lysosomal storage disorder stemming from alpha-galactosidase A deficiency. It can lead to serious health complications, affecting multiple organ systems. Symptoms range from painful neuropathy to gastrointestinal issues, emphasizing the need for effective treatments.
Sangamo Therapeutics is dedicated to transforming groundbreaking science into meaningful therapies for patients coping with serious conditions. Their innovative gene therapy approaches and advanced platforms aim to address critical unmet needs in rare and debilitating diseases.
Frequently Asked Questions
What is isaralgagene civaparvovec?
Isaralgagene civaparvovec is an investigational gene therapy designed to treat Fabry disease by addressing its underlying genetic cause.
What was the main finding of the STAAR study?
The study showed a positive mean annualized eGFR slope at 52 weeks, indicating improved kidney function in participants.
How does the treatment work?
This gene therapy seeks to provide a one-time durable solution by enhancing the production of a critical enzyme needed for lipid metabolism.
When does Sangamo plan to submit its BLA?
Sangamo is preparing to submit a BLA for isaralgagene civaparvovec as early as the first quarter of 2026.
What potential impact does the treatment have on patients?
Patients may experience improved kidney function, better overall health, and a greater quality of life without the ongoing need for enzyme replacement therapies.
